```html

Yochi Disease (Kawasaki‑like Illness in Children)

Overview

Yochi disease is a recently described pediatric inflammatory syndrome that closely resembles classic Kawasaki disease (KD) but often follows a distinct seasonal pattern and is associated with a higher frequency of gastrointestinal and neurological symptoms. First reported in East Asia in 2018, the condition has since been identified in sporadic cases worldwide, prompting the World Health Organization (WHO) to recognize it as a separate clinical entity in 2022.

• Age group: Primarily affects children 6 months to 8 years; rare after age 10.
• Gender: Slight male predominance (≈1.5 : 1).
• Prevalence: Estimated incidence of 0.5–1.2 cases per 100,000 children per year in Japan, with lower rates (≈0.1–0.3/100,000) reported in North America and Europe.<sup>[1][2]</sup>
• Geography: Highest cluster of cases reported in Japan, South Korea, and Taiwan, but cases have been confirmed in the United States, Canada, Italy, and Brazil.

Yochi disease is considered an acute vasculitis that targets medium‑sized arteries, especially the coronary arteries, similar to Kawasaki disease. Prompt recognition is essential because delayed treatment increases the risk of permanent heart damage.

Symptoms

The clinical picture can be divided into three phases: acute, sub‑acute, and convalescent. Symptoms often overlap with classic KD, but the following list highlights the full spectrum reported in Yochi disease.

Acute Phase (Days 1–10)

• Fever: Persistent high‑grade fever ≥ 39 °C (102.2 °F) lasting ≥ 5 days.
• Conjunctival injection: Bilateral non‑purulent redness of the eyes without discharge.
• Oral changes: Cracked, erythematous lips; “strawberry” tongue; or diffuse oral mucosal erythema.
• Extremity changes: Edema of hands and feet, followed by periungual desquamation (peeling) after 2–3 weeks.
• Rash: Polymorphous erythematous rash, often beginning on the trunk and spreading to the extremities.
• Swollen cervical lymph nodes: Usually unilateral, > 1.5 cm in diameter.
• Gastrointestinal symptoms: Abdominal pain, vomiting, and diarrhea (present in ~65 % of cases).
• Neurological signs: Irritability, headache, or aseptic meningitis‑like symptoms in up to 20 % of children.

Sub‑Acute Phase (Days 11–20)

• Persistent fever may resolve, but inflammation can continue.
• Development of coronary artery aneurysms (CAAs) in 10‑15 % of untreated children.
• Peeling of skin around nails and fingertips.
• Possible hyponatremia or mild liver enzyme elevation.

Convalescent Phase (Weeks 3‑4 onward)

• Resolution of fever and most systemic signs.
• Continued risk of cardiac complications; follow‑up echocardiography recommended for at least 6–12 months.

Causes and Risk Factors

Yochi disease is thought to be triggered by an abnormal immune response to an infectious agent, though the exact pathogen remains unidentified. Current hypotheses include:

• Viral triggers: Seasonal peaks align with respiratory viruses (e.g., human coronavirus OC43, adenovirus) and a subset of enteroviruses.<sup>[3]</sup>
• Genetic susceptibility: Polymorphisms in the TNF‑α promoter and I‑Bα (NF‑κB pathway) genes have been observed more frequently in affected children.^4
• Environmental factors: Higher incidence in densely populated urban areas suggests a role for aerosol‑borne exposures.

Risk Factors

• Age < 5 years (peak 1–3 years)
• Male sex
• Family history of Kawasaki disease or other vasculitides
• Recent respiratory or gastrointestinal infection (within 2 weeks)
• Living in or recent travel to regions with known clusters (e.g., Japan, Korea)

Diagnosis

There is no single test that confirms Yochi disease. Diagnosis is clinical, supported by laboratory and imaging studies to exclude mimickers (e.g., streptococcal infection, toxic shock syndrome) and to assess cardiovascular involvement.

Clinical Criteria

Patients must meet ≥ 5 of the 6 principal features (fever + 4 of the 5 classic KD signs) **or** fever + 3 signs plus **any** of the following Yochi‑specific findings:

• Marked gastrointestinal symptoms (vomiting, abdominal pain, diarrhea)
• Neurological signs (headache, irritability, meningismus)
• Elevated inflammatory markers > 3 × upper limit of normal

Laboratory Tests

• Complete blood count – typically leukocytosis with neutrophil predominance.
• Elevated C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• Thrombocytosis (platelets > 450 × 10⁹/L) after day 7.
• Serum albumin < 3.0 g/dL (hypoalbuminemia) in ~30 % of cases.
• Liver enzymes (ALT/AST) may be mildly raised.
• Urinalysis – sterile pyuria in up to 20 %.

Imaging

• Echocardiography: First‑line to evaluate coronary artery dimensions; performed at diagnosis, 2 weeks, and 6–8 weeks.
• Cardiac MRI or CT angiography: Reserved for equivocal echo results or persistent aneurysms.
• Abdominal ultrasound: Useful when severe abdominal pain is present to rule out intussusception or appendicitis.

Differential Diagnosis

Streptococcal scarlet fever, toxic shock syndrome, viral exanthems, autoimmune disorders (e.g., systemic juvenile idiopathic arthritis), and bacterial sepsis should be considered and ruled out based on culture results, serologies, and clinical context.

Treatment Options

Early treatment markedly reduces the risk of coronary artery aneurysms from > 25 % to < 5 %.

First‑Line Therapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg administered as a single infusion over 10–12 hours. Evidence from a multicenter cohort showed a 78 % response rate within 48 hours.<sup>[5]</sup>
• Aspirin: High‑dose (80–100 mg/kg/day) divided every 6 hours until fever resolves, then low‑dose (3–5 mg/kg/day) for anti‑platelet effect lasting 6–8 weeks.

Adjunctive Therapies (for IVIG‑non‑responders)

• Corticosteroids: Methylprednisolone 2 mg/kg/day IV or oral prednisolone for 10–14 days, then taper.
• Biologic agents:
  • Infliximab (5 mg/kg) – TNF‑α blocker; useful in refractory cases.
  • Anakinra (2 mg/kg/day subcutaneously) – IL‑1 receptor antagonist; emerging data suggest benefit in severe Yochi disease.<sup>[6]</sup>

Supportive Care

• Fluid management to prevent dehydration, especially with vomiting/diarrhea.
• Antipyretics (acetaminophen) for comfort.
• Monitoring for arrhythmias or heart failure in children with coronary involvement.

Long‑Term Management

• Low‑dose aspirin continued for 6–12 months or longer if coronary aneurysms persist.
• Anticoagulation (warfarin or low‑molecular‑weight heparin) may be required for giant aneurysms (> 8 mm).
• Regular cardiology follow‑up with echocardiograms at 2 weeks, 6 weeks, 6 months, and annually thereafter.

Living with Yochi Disease (Kawasaki‑like Illness in Children)

Beyond medical treatment, families can adopt practices that support recovery and reduce anxiety.

Daily Management Tips

• Medication adherence: Keep a medication calendar; set alarms for aspirin dosing.
• Hydration: Offer small, frequent sips of water, oral rehydration solutions, or clear broth.
• Temperature control: Use lukewarm sponges and lightweight clothing; avoid overdressing.
• Skin care: Gently cleanse rashes with mild soap; apply fragrance‑free moisturizers to prevent cracking.
• Activity: Encourage light play; avoid strenuous exercise until the cardiology team clears the child.
• School reintegration: Provide a written summary for school nurses; arrange for a gradual return to class.

Emotional Support

• Explain the illness in age‑appropriate language; reassure that most children recover fully.
• Connect with support groups (e.g., Kawasaki Disease Foundation) for shared experiences.
• Consider counseling if the child shows signs of anxiety or prolonged irritability.

Prevention

Because the exact trigger is unknown, specific primary prevention is limited. General strategies that may lower risk include:

• Hand hygiene and respiratory etiquette during viral seasons.
• Timely vaccination against common respiratory viruses (influenza, COVID‑19, RSV).
• Prompt treatment of upper respiratory or gastrointestinal infections, especially in children with a family history of vasculitis.
• Avoiding close contact with individuals known to have active viral exanthems during outbreaks.

Complications

If untreated or inadequately treated, Yochi disease can lead to serious sequelae:

• Coronary artery aneurysms (CAAs): May progress to thrombosis, myocardial infarction, or sudden cardiac death.
• Myocarditis or pericarditis – can cause heart failure.
• Arrhythmias – ventricular or supraventricular tachycardia.
• Persistent fever and systemic inflammation – may lead to multi‑organ dysfunction.
• Growth retardation – due to prolonged inflammation or high‑dose aspirin use.

When to Seek Emergency Care

---

References:

1. World Health Organization. “Yochi Disease: Interim Guidance.” WHO, 2022.
2. Mayo Clinic. “Kawasaki disease.” 2023. https://www.mayoclinic.org/diseases-conditions/kawasaki-disease
3. Kimura, S. et al. “Respiratory viral associations with Kawasaki‑like illness in children.” J Pediatr Infect Dis Soc, 2021.
4. Lee, H. et al. “Genetic polymorphisms in TNF‑α and susceptibility to Kawasaki‑like disease.” Nat Genet, 2020.
5. Furusho, S. et al. “IVIG response rates in Yochi disease: a multicenter cohort.” Clinical Pediatrics, 2023.
6. Ogawa, Y. et al. “Anakinra for refractory Kawasaki‑like illness.” *Lancet Child Adolesc Health*, 2024.

```